CA
ERNA icon

Callahan Advisors’s Eterna Therapeutics ERNA Stock Holding History

Callahan Advisors’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1
Closed -$41K – 125
2019
Q4 		$41K Hold
1
– – 0.01% 133
2019
Q3 		$63K Hold
1
– – 0.01% 132
2019
Q2 		$71K Hold
1
– – 0.01% 135
2019
Q1 		$76K Hold
1
– – 0.01% 132
2018
Q4 		$37K Hold
1
– – 0.01% 129
2018
Q3 		$84K Hold
1
– – 0.02% 136
2018
Q2 		$84K Hold
1
– – 0.02% 125
2018
Q1 		$128K Hold
1
– – 0.03% 118
2017
Q4 		$79K Hold
1
– – 0.02% 123
2017
Q3 		$115K Hold
1
– – 0.02% 121
2017
Q2 		$128K Hold
1
– – 0.03% 120
2017
Q1 		$162K Hold
1
– – 0.04% 119
2016
Q4 		$160K Buy
+1
New +$120K 0.04% 111

Other funds holding ERNA

NSIM
North Star Investment Management Chicago, Illinois $1.65B AUM 20.56% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Callahan Advisors's ERNA Position: Q1 2020 in Review

Callahan Advisors sold out of Eterna Therapeutics (ERNA) in Q1 2020, closing a stake of 1 share — an estimated $41K sold.

Callahan Advisors first reported a position in ERNA in Q4 2016 and held it in 13 quarters. The position peaked at $162K in Q1 2017. 7 funds tracked by Wall St. Rank hold ERNA as of Q1 2020.

  • Callahan Advisors reported no remaining Eterna Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Callahan Advisors sold 1 Eterna Therapeutics share in Q1 2020, an estimated $41K.
  • Callahan Advisors first reported a position in Eterna Therapeutics in Q4 2016 and held it in 13 quarters.
  • Callahan Advisors's Eterna Therapeutics position peaked at $162K in Q1 2017.
  • 7 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q1 2020.

Based on Callahan Advisors's 13F filing for Q1 2020, filed 6 Apr 2020.